Literature DB >> 15337426

Image-guided breast biopsy and management of high-risk lesions.

Wendie A Berg1.   

Abstract

Across several series, the sensitivity of sonographically guided 14-gauge core biopsy is 95%, and the repeat biopsy rate averages 11%. Success of stereotactic biopsy requires obtaining larger volumes of tissue when sampling calcifications; use of vacuum-assisted devices results in comparable sensitivities. For MR imaging-guided percutaneous biopsy,success rates of 95% to 99% have been achieved. Independent of guidance method or the amounts of tissue acquired, the following diagnoses on percutaneous biopsy should generally prompt excision: atypical ductal hyperplasia, lobular neoplasia, radial sclerosing lesions, benign and atypical papillary lesions, and possible phyllodes tumor. Mucocele-like lesions may merit excision. Columnar alteration without atypia probably does not require excision, although further study is needed.

Entities:  

Mesh:

Year:  2004        PMID: 15337426     DOI: 10.1016/j.rcl.2004.04.002

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN: 0033-8389            Impact factor:   2.303


  14 in total

1.  MR-guided breast biopsy and hook wire marking using a low-field (0.23 T) scanner with optical instrument tracking.

Authors:  Roberto Blanco Sequeiros; Heli Reinikainen; Andreas M Blanco Sequeiros; Teuvo Vaara; Risto Ojala; Eija Pääkkö; Osmo Tervonen
Journal:  Eur Radiol       Date:  2006-09-22       Impact factor: 5.315

Review 2.  Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer?

Authors:  Gulisa Turashvili; Malcolm Hayes; Blake Gilks; Peter Watson; Samuel Aparicio
Journal:  Virchows Arch       Date:  2008-04-24       Impact factor: 4.064

3.  Risk factors for malignancy in benign papillomas of the breast on core needle biopsy.

Authors:  So-Youn Jung; Han-Sung Kang; Youngmee Kwon; Sun Young Min; Eun-A Kim; Kyoung Lan Ko; Seeyoun Lee; Seok Won Kim
Journal:  World J Surg       Date:  2010-02       Impact factor: 3.352

Review 4.  Cystic breast masses and the ACRIN 6666 experience.

Authors:  Wendie A Berg; Alan G Sechtin; Helga Marques; Zheng Zhang
Journal:  Radiol Clin North Am       Date:  2010-09       Impact factor: 2.303

5.  Borderline breast lesions: comparison of malignancy underestimation rates with 14-gauge core needle biopsy versus 11-gauge vacuum-assisted device.

Authors:  Viviana Londero; Chiara Zuiani; Anna Linda; Luisa Battigelli; Giovanni Brondani; Massimo Bazzocchi
Journal:  Eur Radiol       Date:  2011-01-12       Impact factor: 5.315

6.  Value of breast MRI for patients with a biopsy showing atypical ductal hyperplasia (ADH).

Authors:  Keiko Tsuchiya; Naoko Mori; David V Schacht; Deepa Sheth; Gregory S Karczmar; Gillian M Newstead; Hiroyuki Abe
Journal:  J Magn Reson Imaging       Date:  2017-03-10       Impact factor: 4.813

Review 7.  Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection?

Authors:  Francesco Sardanelli; Franca Podo
Journal:  Eur Radiol       Date:  2006-09-29       Impact factor: 5.315

8.  Analysis of false-negative results after US-guided 14-gauge core needle breast biopsy.

Authors:  Ji Hyun Youk; Eun-Kyung Kim; Min Jung Kim; Jin Young Kwak; Eun Ju Son
Journal:  Eur Radiol       Date:  2009-10-28       Impact factor: 5.315

9.  Sonographically guided core biopsy of the breast: comparison of 14-gauge automated gun and 11-gauge directional vacuum-assisted biopsy methods.

Authors:  Nariya Cho; Woo Kyung Moon; Joo Hee Cha; Sun Mi Kim; Seung Ja Kim; Sin Ho Lee; Hye Kyung Chung; Kyung Soo Cho; In Ae Park; Dong-Young Noh
Journal:  Korean J Radiol       Date:  2005 Apr-Jun       Impact factor: 3.500

10.  Ultrasound Guided Core Biopsy versus Fine Needle Aspiration for Evaluation of Axillary Lymphadenopathy in Patients with Breast Cancer.

Authors:  Marie A Ganott; Margarita L Zuley; Gordon S Abrams; Amy H Lu; Amy E Kelly; Jules H Sumkin; Mamatha Chivukula; Gloria Carter; R Marshall Austin; Andriy I Bandos
Journal:  ISRN Oncol       Date:  2014-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.